Population Health Spotlight Speaker Series: Dr. Gerberding
With U.S. public health facing proposed policy cuts and rising inequities in early 2026, a former CDC director now leading NIH's foundation speaks on population health amid heightened threats to the systems that protect millions.
Key takeaways
- •Recent policy proposals in the new administration risk dismantling key public health infrastructure, potentially worsening chronic disease burdens and health disparities affecting tens of millions.
- •Dr. Julie Gerberding's role at the Foundation for the National Institutes of Health positions her to highlight funding and innovation needs as federal budgets tighten and private philanthropy becomes more critical.
- •Population health efforts now contend with tensions between evidence-based prevention and emerging political priorities that favor individual-focused approaches over community-wide interventions.
Public Health at a Crossroads
The American Public Health Association (APHA) has listed the Population Health Spotlight Speaker Series event featuring Dr. Julie Louise Gerberding for March 11, 2026, as a live webinar entry on its events page, though specific registration details are not yet prominent or directly linked there.
Dr. Gerberding, former CDC director during the 2000s and now President and CEO of the Foundation for the National Institutes of Health (FNIH), brings decades of experience in infectious disease response and population-level health strategy. Her appearance comes at a moment when public health institutions face scrutiny and potential restructuring following the 2024 election outcomes and early 2025 policy shifts.
In late 2025, APHA convened amid warnings that proposed changes could jeopardize core public health systems, including surveillance, vaccination programs, and equity initiatives. These developments follow years of strain from pandemic aftermath, chronic disease epidemics, and workforce shortages. Affordability concerns dominate public sentiment, with surveys showing widespread worry over health care costs outpacing other household expenses.
The stakes involve real consequences: delays or cuts in federal funding could lead to reduced outbreak detection, higher rates of preventable diseases, and widened gaps in life expectancy across socioeconomic and racial lines. States already grapple with Medicaid pressures from disenrollment and adverse selection, while employers face escalating costs from chronic conditions and new pharmaceutical innovations like GLP-1 drugs.
Non-obvious tensions include the push-pull between traditional public health's focus on upstream prevention and newer narratives emphasizing personal responsibility or market-driven solutions. Philanthropic entities like FNIH, which bridges government research and private resources, may play an outsized role in sustaining progress if federal support wanes, raising questions about accountability and long-term equity in who sets health priorities.
Sources
- https://www.apha.org/events-and-meetings
- https://www.apha.org/events-and-meetings/apha-calendar/population-health-spotlight-speaker-series-gerberding
- https://www.apha.org/
- https://drexel.edu/dornsife/news/events/details?eid=45176&iid=118119
- https://www.npr.org/sections/shots-health-news/2025/11/04/nx-s1-5597970/apha-maha-american-public-health-association
- https://www.mckinsey.com/industries/healthcare/our-insights/what-to-expect-in-us-healthcare
- https://www.kff.org/public-opinion/kff-health-tracking-poll-health-care-costs-expiring-aca-tax-credits-and-the-2026-midterms